


# GSK delivers continued strong performance and upgrades 2024 guidance

"GSK's momentum this year continues with excellent second quarter performance, reflecting strong operational execution and the strengthening breadth of our portfolio to both prevent and treat disease. Q2 sales grew in all areas, with Specialty Medicines in particular benefitting from new product launches in oncology and HIV.

In R&D, so far this year, we have secured approvals or filings for 10 major opportunities and reported positive data from 7 phase III trials. We have also strengthened capabilities in key technology platforms and completed investments to develop new mRNA vaccines, ultra-long-acting HIV medicines and a promising new medicine for severe asthma. All this supports our future growth and confidence to bring meaningful innovation to patients."

**Emma Walmsley**  
Chief Executive Officer, GSK



**Vaccines**  
**£2bn**  
+1%, +3%  
including and excluding COVID-19 solutions

**Specialty Medicines**  
**£3bn** +22%  
with HIV +13%

**General Medicines**  
**£2.9bn** +12%

Core operating profit  
**£2.5bn**  
+18%, +21%  
including and excluding COVID-19 solutions

Total EPS  
**28.8p**  
-27%

Core EPS  
**43.4p**  
+13%, +17%  
including and excluding COVID-19 solutions

Dividend  
**15p**

**70**  
vaccines and medicines in pipeline

**10**  
approvals or filings secured for major opportunities in H1

**7**  
positive data readouts on phase III trials in H1

Journalists, media and investors see press release on [www.gsk.com](http://www.gsk.com) for full details on Q2 2024.

Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on pages 62 and 64 of the press release.

Product group sales may not add to total sales due to rounding.

References to growth are at constant exchange rates (CER) unless stated otherwise.